Low Temperature Sterilization Market Report: Market Size & Forecast 2026

Low temperature sterilization covers a range of methods including ethylene oxide (EtO), hydrogen peroxide plasma, peracetic acid, vaporized hydrogen peroxide, and other specialized processes designed for heat-labile medical devices and pharmaceutical packaging. The global sterilization services segment alone was valued at approximately $3.52 billion in 2024 and is projected to reach $5.49 billion by 2030 at a 7.9% compound annual growth rate, forming a significant component of the broader low temperature sterilization market. Endoscope reprocessing, a critical sub-segment reliant on low-temperature chemical and high-level disinfection methods, is growing even faster at an estimated 9.4% CAGR, reaching $4.24 billion by 2030 from $2.49 billion in 2024.

• •The broader infection control market in Europe alone was valued at $14.14 billion in 2024, highlighting the large addressable base for sterilization-related products and services
• •Endoscope reprocessing reached $2.71 billion in 2025 and is among the fastest-growing segments due to rising minimally invasive procedure volumes
• •Market growth reflects increasing regulatory mandates for validated sterilization processes across healthcare, pharmaceutical, and life sciences sectors

Rising awareness of healthcare-associated infections (HAIs) and associated regulatory penalties has made validated low temperature sterilization a non-negotiable requirement for hospitals, surgery centers, and medical device manufacturers globally. The growing prevalence of complex, heat-sensitive medical devices, including endoscopes, catheters, robotic surgical instruments, and implantable electronics, continues to expand the addressable market for non-steam sterilization technologies. Additionally, the generic pharmaceutical industry's sustained growth as a healthcare cost-containment mechanism drives consistent demand for validated terminal sterilization services for drug products and packaging.

• •Healthcare-associated infection prevention regulations in North America, Europe, and increasingly Asia-Pacific mandate validated sterilization for reusable medical devices
• •Advances in minimally invasive and robotic surgery have created new sterilization requirements for intricate, heat-labile instruments incompatible with steam
• •The global pharmaceutical sector's continued reliance on contract sterilization services supports steady demand across terminal sterilization modalities

The market spans multiple product and service categories including contract sterilization outsourcing services, terminal sterilization systems for in-house hospital use, sterilant consumables, and associated reprocessing equipment. Geographically, North America represents the largest regional market, supported by extensive healthcare infrastructure, stringent FDA sterilization validation requirements, and high surgical procedure volumes. Europe constitutes a major regional market at approximately $14.14 billion in 2024 for the broader infection control category, with growth propelled by EU medical device regulations and infection prevention standards.

• •The European infection control market is projected to grow from $14.99 billion in 2025 to $20.58 billion by 2030 at a 6.6% CAGR
• •Asia-Pacific is emerging as the fastest-growing regional market driven by expanding hospital construction, medical device manufacturing, and improving healthcare infection control standards
• •Contract sterilization service outsourcing represents a significant and growing share as manufacturers and healthcare facilities seek specialized, validated sterilization expertise

Who are the notable companies in the industry?

The competitive landscape is moderately consolidated at the global tier, driven by high barriers to entry including validated facility capital, regulatory licensing, and quality system compliance that favor established players. **STERIS plc** and **Getinge AB** anchor the high-volume end of the spectrum with vertically integrated portfolios spanning system hardware, sterilant chemicals, biological indicators, and process monitoring. **Advanced Sterilization Products (Fortive)** and **Cantel Medical** compete aggressively through differentiated product platforms and service network depth, while **Solventum Corporation** leverages specialized chemistry expertise to serve targeted end-market niches. **Belimed** and **MMM Group** distinguish themselves through precision-engineered sterilization systems emphasizing automation and data connectivity. **Noxilizer** occupies a distinct position with nitrogen dioxide (NO₂) and e-beam technology, offering a non-traditional alternative to established low-temperature modalities. Contract sterilization service providers operate within this supplier ecosystem, reinforcing concentration at the global tier and reinforcing the value-chain interdependency between hardware OEMs and outsourced service channels.

• •Contract sterilization services exhibit moderate-to-high consolidation at the global level due to the capital intensity of building and maintaining compliant facilities
• •Key process technology routes include ethylene oxide gas for wide-ranging material compatibility, vaporized hydrogen peroxide for faster cycle times, and peracetic acid for liquid immersion applications
• •Global sterilization capacity is concentrated in North America and Western Europe, with accelerating capacity expansion in Southeast Asia, India, and China to serve growing pharmaceutical and medical device manufacturing bases

What are the recent trends and outlook?

The market is experiencing a structural shift toward single-use medical devices and packaging as a complementary response to sterilization bottlenecks, though this trend is balanced by sustainability considerations driving reusable device programs with validated reprocessing. Emerging alternative technologies including supercritical CO2, atmospheric plasma, and low-temperature vaporized hydrogen peroxide systems are gaining regulatory acceptance and commercial traction, particularly in markets seeking to reduce EtO emissions. Long-term growth through 2030 and beyond is underpinned by the projected continuation of global healthcare infrastructure investment, aging population demographics, and ongoing tightening of infection control standards across both developed and emerging markets.

• •Environmental and regulatory pressure on EtO emissions is accelerating adoption of alternative low-temperature sterilization modalities in markets with strict air quality standards
• •The shift toward single-use medical devices in some applications creates both competitive dynamics and expanded sterilization demand for disposable product lines
• •Market projections through 2030 reflect continued above-GDP growth rates, supported by healthcare sector expansion in emerging markets and ongoing medical technology innovation